December 14, 2021
Shionogi and StemRIM, an Osaka University spinout, said on December 13 that their “regeneration-inducing medicine” candidate redasemtide met the primary endpoint in a PII clinical trial targeting acute ischemic stroke. The placebo-controlled, double-blind, randomized, controlled trial was designed to gauge...read more